PMID- 34789133
OWN - NLM
STAT- MEDLINE
DCOM- 20220617
LR  - 20221207
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 18
IP  - 8
DP  - 2022
TI  - Does Insulin Use Worsen the Prognosis of COVID-19 Patients with Type 2 Diabetes 
      Mellitus? A Current Update.
PG  - e171121197988
LID - 10.2174/1573399818666211117110113 [doi]
AB  - BACKGROUND: Insulin has recently received special attention concerning its use in 
      COVID-19 patients. Although controversial, insulin can be able to worsen the 
      prognosis of COVID-19 patients with Type 2 Diabetes Mellitus (T2DM) through an 
      inflammatory pathway. This uncertain aspect brings a new perspective related to 
      insulin use in this pandemic era. OBJECTIVE: We tried to collect and analyze 
      various studies related to this issue to provide a complete picture of the 
      prognosis of insulin use in COVID-19 patients with T2DM. METHODS: We 
      comprehensively searched PubMed, Cochrane CENTRAL, Embase, EBSCO CINAHL, MEDLINE, 
      and grey literature databases for studies investigating the effect of insulin on 
      COVID-19 outcomes, including mortality, hospitalization, disease progression, 
      other prognostic surrogates. Records were screened against the eligibility 
      criteria. RESULTS: 2556 articles were retrieved and were screened. A total of 8 
      studies were included in the final analysis. There are no studies with solid 
      evidence supporting the effect of insulin treatment on the worsening of the 
      prognosis of COVID-19 patients with T2DM. Although several studies have shown 
      that insulin is associated with a poor prognosis, most studies have not 
      considered confounders. This certainly makes it challenging to analyze the 
      effects of insulin independently. CONCLUSION: We propose that COVID-19 patients 
      with T2DM continue to receive insulin, but with careful observation of the risk 
      of disease progression.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Wiyarta, Elvan
AU  - Wiyarta E
AD  - Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
FAU - Wisnu, Wismandari
AU  - Wisnu W
AD  - Division of Endocrinology, Metabolism and Diabetes, Internal Medicine Department, 
      Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas 
      Indonesia, Jakarta, Indonesia.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 0 (Insulin)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Disease Progression
MH  - Humans
MH  - Insulin/adverse effects
MH  - Prognosis
MH  - *COVID-19 Drug Treatment
OTO - NOTNLM
OT  - COVID-19
OT  - Insulin
OT  - diabetes
OT  - hospitalization
OT  - mortality
OT  - prognosis
EDAT- 2021/11/19 06:00
MHDA- 2022/06/18 06:00
CRDT- 2021/11/18 05:44
PHST- 2021/07/14 00:00 [received]
PHST- 2021/08/17 00:00 [revised]
PHST- 2021/09/13 00:00 [accepted]
PHST- 2021/11/19 06:00 [pubmed]
PHST- 2022/06/18 06:00 [medline]
PHST- 2021/11/18 05:44 [entrez]
AID - CDR-EPUB-118878 [pii]
AID - 10.2174/1573399818666211117110113 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2022;18(8):e171121197988. doi: 
      10.2174/1573399818666211117110113.